4.1 Closure and visual improvement rates according to treatment
Transcatheter closure of VSD was first described by Lock[21] in 1988. In the last four decades, TCC for PIVSD has justified a feasible and less invasive procedure. Our results show that the successful device implantation rate was 89.7% (95%CI: 0.772- 1.021). The 30- day mortality rate was approximately 31.5% (95%CI of 0.149- 0. 482) and as high as 25.3% (95%CI: 0.072-0.434) when primary closure at the acute phase (<2 weeks). It is comparatively lower than the surgical repair treatment within three weeks and more prolonged than three weeks ,respectively 50% and 38%[22-23]. Data from several sources have identified the patients who underwent successful percutaneous closure showed a trend toward a satisfactory long-term outcome[24-25].
In the comparison of TCC to surgical closure, the pooled analysis of two studies showed no significant difference in 30-day mortality, immediate shunt reduction. The small number of studies limits these conclusions. It is of necessity for future randomized controlled trials to demonstrate TCC compared with surgical closure.